By Victor Abrego
The evaluation of non-mutagenic impurities (NMI) is a critical aspect of pharmaceutical development, ensuring that products are safe for human consumption. While the ICH Q3A and Q3B guidelines establish a general framework, challenges remain in qualifying impurities that are new or at higher concentrations than previously evaluated.
How are non-mutagenic impurities evaluated?
The evaluation of NMIs is based on a risk approach, considering exposure, route of administration, physicochemical properties and toxicological profile. For impurities already present as metabolites in animals or humans, their qualification can be derived from pre-existing active ingredient data(API), avoiding additional studies. However, when an impurity is not characterized, structural elucidation studies are required.
New methodologies for the qualification of NMIs
Since traditional evaluation may rely on animal studies, alternative methodologies have been developed to reduce this need without compromising safety. Some of the tools that are recommended are:
- Read-Across (RAX): Allows extrapolation of data from similar compounds with known toxicological profiles.
- QSAR and computational toxicology: Predictive models that assess the toxicological risk of an impurity based on its chemical structure.
- In vitro studies: Advanced cellular models that help determine toxic effects without the need for testing in living organisms.
- Acceptable Level (AL) calculation: Estimation of a safe dose based on available toxicological data, considering factors such as bioavailability and duration of treatment.
When are in vivo studies required?
Only in cases where alternative methodologies are not sufficient, animal studies are considered. However, these must be well designed, using highly purified samples of the impurity and complying with ethical principles to minimize their impact.
The analysis of non-mutagenic impurities is evolving towards more precise and ethical approaches, prioritizing the use of computational and in vitro data. Understanding these strategies is key to implementing strategies to justify product-specific impurity limits.
If you wish to explore more about these methodologies and their application in risk analysis, click on the box below.